MX2023009392A - Anticuerpo anti-vegf y uso del mismo. - Google Patents
Anticuerpo anti-vegf y uso del mismo.Info
- Publication number
- MX2023009392A MX2023009392A MX2023009392A MX2023009392A MX2023009392A MX 2023009392 A MX2023009392 A MX 2023009392A MX 2023009392 A MX2023009392 A MX 2023009392A MX 2023009392 A MX2023009392 A MX 2023009392A MX 2023009392 A MX2023009392 A MX 2023009392A
- Authority
- MX
- Mexico
- Prior art keywords
- protein
- vegf antibody
- binding
- vegf
- isolated antigen
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona una proteína de unión a antígeno aislada capaz de unirse a la proteína VEGF y/o capaz de bloquear la unión de la proteína VEGF a la proteína VEGFR. Además se proporciona el uso de la proteína de unión a antígeno aislada en la preparación de un fármaco.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110183560 | 2021-02-10 | ||
| PCT/CN2022/075600 WO2022171109A1 (zh) | 2021-02-10 | 2022-02-09 | 抗vegf抗体及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009392A true MX2023009392A (es) | 2023-11-09 |
Family
ID=82838272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009392A MX2023009392A (es) | 2021-02-10 | 2022-02-09 | Anticuerpo anti-vegf y uso del mismo. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4292661A1 (es) |
| JP (1) | JP2024506664A (es) |
| KR (1) | KR20230142838A (es) |
| CN (1) | CN116897164A (es) |
| AU (1) | AU2022220965A1 (es) |
| BR (1) | BR112023016095A2 (es) |
| CA (1) | CA3207763A1 (es) |
| IL (1) | IL305092A (es) |
| MX (1) | MX2023009392A (es) |
| TW (1) | TW202246328A (es) |
| WO (1) | WO2022171109A1 (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101148474B (zh) * | 2006-09-21 | 2014-06-11 | 上海杰隆生物工程股份有限公司 | 人源人血管内皮生长因子单克隆抗体及其制备方法 |
| CN102002104A (zh) * | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| AU2017273169B2 (en) * | 2016-06-03 | 2020-07-30 | Aimed Bio Inc. | Method for screening antibody using patient-derived tumor spheroids |
| CN114008075A (zh) * | 2019-07-19 | 2022-02-01 | 神州细胞工程有限公司 | 人源化抗vegf单克隆抗体 |
-
2022
- 2022-02-09 MX MX2023009392A patent/MX2023009392A/es unknown
- 2022-02-09 KR KR1020237030457A patent/KR20230142838A/ko unknown
- 2022-02-09 EP EP22752269.5A patent/EP4292661A1/en active Pending
- 2022-02-09 TW TW111104769A patent/TW202246328A/zh unknown
- 2022-02-09 WO PCT/CN2022/075600 patent/WO2022171109A1/zh active Application Filing
- 2022-02-09 IL IL305092A patent/IL305092A/en unknown
- 2022-02-09 CN CN202280014211.3A patent/CN116897164A/zh active Pending
- 2022-02-09 BR BR112023016095A patent/BR112023016095A2/pt unknown
- 2022-02-09 CA CA3207763A patent/CA3207763A1/en active Pending
- 2022-02-09 JP JP2023548780A patent/JP2024506664A/ja active Pending
- 2022-02-09 AU AU2022220965A patent/AU2022220965A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202246328A (zh) | 2022-12-01 |
| CN116897164A (zh) | 2023-10-17 |
| IL305092A (en) | 2023-10-01 |
| BR112023016095A2 (pt) | 2023-11-14 |
| AU2022220965A1 (en) | 2023-08-31 |
| CA3207763A1 (en) | 2022-08-18 |
| WO2022171109A1 (zh) | 2022-08-18 |
| KR20230142838A (ko) | 2023-10-11 |
| EP4292661A1 (en) | 2023-12-20 |
| JP2024506664A (ja) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019255744A8 (en) | IL-15/IL-15Ra heterodimeric Fc fusion proteins and uses thereof | |
| DOP2023000165A (es) | Anticuerpos de unión a cd3 | |
| MX2020013169A (es) | Conjugados de camptotecina. | |
| BR112018076767A2 (pt) | anticorpos de ligação a cd3 | |
| AU2018263862A1 (en) | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | |
| PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
| MX2020009152A (es) | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. | |
| NZ603498A (en) | Human cytomegalovirus neutralizing antibodies and use thereof | |
| MX2021010531A (es) | Proteina de fusion bifuncional y uso farmaceutico de la misma. | |
| EP3554544A4 (en) | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE | |
| NZ594514A (en) | Interleukin-17 BINDING PROTEINS | |
| MX2020009116A (es) | Proteinas triespecificas de union a antigenos. | |
| MX2021012692A (es) | Anticuerpos anti-mertk y sus metodos de uso. | |
| EP3915581A4 (en) | NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| MX2022004291A (es) | Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos. | |
| EP4146168A4 (en) | USE OF ANTI-IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | |
| CL2023001064A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| MX2021001085A (es) | Formulaciones y composiciones farmaceuticas que comprenden una proteina de union a antigeno enmascarada. | |
| MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). | |
| MX2023009392A (es) | Anticuerpo anti-vegf y uso del mismo. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use |